Latest JN-International Medical Corporation Stories
Approval aligns with Centers for Disease Control and Prevention's recommendations for meningococcal vaccination SWIFTWATER, Pa., Sept.
DUBLIN, May 19, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/rd8s6p/meningococcal)
A new technique that accurately determines the risk of infants in endemic countries developing clinical malaria could provide a valuable tool for evaluating new malaria prevention strategies and vaccines.
SAN DIEGO, May 17, 2011 /PRNewswire/ -- Pfenex Inc.'s Reagent Proteins division announced today that it has submitted a Biologics Master File (BMF) to the United States Food and Drug Administration for its cGMP grade CRM197 carrier protein to support the development of conjugate vaccine products by its partners. Reagent Proteins is supplying cGMP grade CRM197 carrier protein to multiple partners in support of their novel conjugate vaccine development efforts.
ROCKVILLE, Md., April 19 /PRNewswire/ -- Protein Potential LLC has received support from the National Institute of Allergy and Infectious Diseases (NIAID) of the NIH in the form of a Phase II Small Business Innovation Research (SBIR) Grant.
Dutch biopharma company Crucell N.V.
- To give a box on the ear to.